NCT03709758进行中（未招募）1 期
Phase 1b Study of Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve Subjects With Acute Myelogenous Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Maximum Tolerated Dose (Induction)
研究概览
简要总结
This research study is studying the combination of venetoclax and chemotherapy as a possible treatment for acute myelogenous leukemia (AML).
The drugs involved in this study are:
- Venetoclax
- Daunorubicin
- Cytarabine
详细描述
This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved venetoclax for this specific disease but it has been approved for other uses.
In this research study, the investigators are combining the use of venetoclax (the investigational drug being studied) with chemotherapy drugs daunorubicin and cytarabine. The investigators are looking to determine the highest dose of venetoclax that can be given safely in combination with these chemotherapy drugs.
Depending on when the participant join the study, the participant may participate in part 1 (induction with venetoclax escalation), part 2 (consolidation with venetoclax escalation), or part 3 (an expansion cohort utilizing the maximum tolerated doses identified in parts 1 and 2). The study doctor will tell the participant which part of the study they will join.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with AML who are newly diagnosed according to the WHO 2016 Classification and previously untreated with the exception of hydroxyurea. ATRA pretreatment for suspected APL for less than 5 days is allowed. Eligible patients with AML arising from an antecedent hematologic disease (AHD) including MDS, may have been treated for their prior hematologic disease (except for allogenic transplant).
- •AML patients include de-novo AML, AML evolving from MDS or other AHD and AML after previous cytotoxic therapy or radiation (secondary AML).
- •For a diagnosis of AML, a bone marrow or peripheral blast count of 20% or more is required.
- •In AML with monocytic or myelomonocytic differentiation, monoblasts and promonocytes, but not abnormal mature monocytes, are counted as blast equivalents.
- •Patients must be ≥18 and ≤60 years old.
- •Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to
- •(See protocol Appendix D.)
- •LVEF ≥ 45% by MUGA or ECHO at screening.
- •Adequate renal function as demonstrated by a calculated creatinine clearance ≥ 50 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula.
- •Adequate liver function as demonstrated by:
- •aspartate aminotransferase (AST) ≤ 2.5 × ULN*
- •alanine aminotransferase (ALT) ≤ 2.5× ULN*
- •total bilirubin ≤ 1.5 × ULN*
- •Unless considered due to leukemic organ involvement.
- •Subjects with Gilbert's Syndrome may have a total bilirubin > 1.5 × ULN per discussion with the overall study PI
- •Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug.
- •Females of childbearing potential (i.e., not postmenopausal for at least 1 year or not surgically sterile) must have negative results by a serum pregnancy test performed within 7 days of day
- •Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
排除标准
- •Subject has acute promyelocytic leukemia, inversion16, t(8;21) or FLT3 mutant AML as described below. Contact PI with questions.
- •Inversion 16 and t(8;21): CBF chromosomal abnormalities may be assessed by molecular (PCR), metaphase cytogenetics, or FISH
- •FLT3: ITD or a point mutation in the TKD loop of variant allele fractions ≥5% by PCR, capillary electrophoresis, or NGS panel capable of defining FLT3 allelic burden
- •Subject has known active CNS involvement with AML.
- •Subject has tested positive for HIV (due to potential drug-drug interactions between antiretroviral medications and venetoclax, as well as anticipated venetoclax mechanism-based lymphopenia that may potentially increase the risk of opportunistic infections). Note: HIV testing is not required.
- •Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months. (Hepatitis B or C testing is not required). Subjects with serologic evidence of prior vaccination to HBV [i.e., HBs Ag-, and anti-HBs+] are allowed.
- •Subject has received the following within 7 days prior to the initiation of study treatment:
- •Strong or moderate CYP3A inducers (see Appendix C)
- •Strong and moderate CYP3A inhibitors (see Appendix C)
- •Subject has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit within 3 days prior to the initiation of study treatment.
- •Subject has a cardiovascular disability status of New York Heart Association Class ≥
- •Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.
- •Subject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study.
- •Subject has chronic respiratory disease that requires continuous oxygen use.
- •Subject has a malabsorption syndrome or other condition that precludes enteral route of administration.
- •Subject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: uncontrolled systemic infection.
- •Subject has a history of other malignancies prior to study entry, with the exception of:
- •Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;
- •Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
- •Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
- •Prior malignancies treated with (surgery+/- chemotherapy+/- radiation) that have remained disease free for at least two years after completion of therapy
- •Subject has a white blood cell count > 25 × 109/L. Note: Hydroxyurea is permitted to meet this criterion.
- •Subject treated with any form of chemotherapy, immunotherapy, or investigative agent within 1 month of enrollment.
研究组 & 干预措施
Venetoclax+Daunorubicin+Cytarabine
Experimental
- Venetoclax administered orally on days 1 to 11 daily
- Daunorubicin administered intravenously on days 2-4
- Cytarabine administered on days 2-8 by continuous IV infusion
干预措施: Daunorubicin (Drug)
Venetoclax+Daunorubicin+Cytarabine
Experimental
- Venetoclax administered orally on days 1 to 11 daily
- Daunorubicin administered intravenously on days 2-4
- Cytarabine administered on days 2-8 by continuous IV infusion
干预措施: Venetoclax (Drug)
Venetoclax+Daunorubicin+Cytarabine
Experimental
- Venetoclax administered orally on days 1 to 11 daily
- Daunorubicin administered intravenously on days 2-4
- Cytarabine administered on days 2-8 by continuous IV infusion
干预措施: Cytarabine (Drug)
结局指标
主要结局
Maximum Tolerated Dose (Induction)
时间窗: 2 years
To determine a safe and tolerable dose of venetoclax that can be given in combination with standard induction therapy to patients with newly diagnosed AML.
Maximum Tolerated Dose (Consolidation)
时间窗: 2 years
To determine a safe and tolerable dose of venetoclax and that can be given with a cycle of high dose cytarabine in consolidation after achievement of remission with induction therapy at the established MTD of venetoclax.
次要结局
- Exploratory analysis concerning the impact of pre-therapy disease factors including mutational profile on outcome in AML patients who receive venetoclax in combination with standard chemotherapy.(2 years)
- Determine the pharmacodynamic effects of combo venetoclax with standard chemotherapy in AML on apoptosis and other intracellular events in AML blasts exposed in patients to a combination of venetoclax plus standard induction chemo.(2 years)
- Exploratory analysis concerning the impact of BH3 profiling on response when venetoclax is combined with standard induction and consolidation chemotherapy in AML.(2 years)
- Complete Response Rate(2 years)
研究者
Richard Stone, MD
Principal Investigator
Dana-Farber Cancer Institute
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALLLeukemiaNCT03319901Dana-Farber Cancer Institute82
招募中
1 期
Venetoclax Basket Trial for High Risk Hematologic MalignanciesMyelodysplastic Syndromes, de NovoMyelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously TreatedTreatment-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed RemissionLymphoblastic Lymphoma, in RelapseLymphoblastic Lymphoma, RefractoryAcute Leukemia of Ambiguous Lineage in RelapseAcute Leukemia of Ambiguous LineageNCT05292664Andrew E. Place, MD30
终止
1 期
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic SyndromeTherapy-Related Myelodysplastic SyndromeNCT04550442M.D. Anderson Cancer Center34
招募中
2 期
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT05955261St. Jude Children's Research Hospital70
终止
1 期
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)Acute Myeloid LeukemiaNCT06158100Antonio M Jimenez Jimenez2